February 4, 2026
In 2025, the Plasma Protein Therapeutics Association (PPTA) made meaningful progress in advancing patient access to plasma-derived therapies amid a complex global policy and regulatory environment. Through collaboration, data-driven leadership, and strategic advocacy, PPTA and its members strengthened the plasma ecosystem across the United States and Europe.
Read PPTA’s 2025 Annual Report
U.S. Advocacy and Legislative Progress
PPTA expanded awareness of plasma-derived therapies on Capitol Hill, growing the bipartisan Congressional Plasma Caucus from 29 to 46 members and engaging more than 100 Congressional offices. These efforts supported key policy wins, including progress on tariff exemptions for pharmaceutical inputs and successful state-level legislation in Louisiana to streamline plasma center operations. Advocacy also continued across California, New Jersey, and Washington.
Strengthening Access and Systems in Europe
In Europe, PPTA helped secure recognition of the specialized plasma supply chain in amendments to the EU Critical Medicines Act, which is an important step toward safeguarding patient access. PPTA also advanced donor safety through new national donor registry systems and presented new research on plasma-derived medicinal product reimbursement and access to inform evidence-based policymaking across the EU.
Data-Driven Leadership and Regulatory Engagement
Scientific credibility remained central to PPTA’s work. The Cohort of Repeat Donor Experiences (CORE) Study received Institutional Review Board approval and is preparing for a 2026 pilot launch to assess donor health outcomes. Throughout the year, PPTA engaged closely with U.S. and European regulators to modernize guidance, protect plasma center operations, and ensure evolving regulations reflect the realities of plasma collection and manufacturing.
Raising Awareness Worldwide
International Plasma Awareness Week (IPAW) 2025 united donors, patients, and policymakers around the theme “Plasma Powers Possibility.” Global campaigns, policy discussions, and patient stories reinforced a shared message: plasma donation saves lives and sustained donor engagement is essential. See more from this year’s campaign at www.plasmaweek.org.
Looking Ahead
As PPTA moves into 2026, priorities include advocating for proportionate regulatory approaches, supporting EU substances of human origin (SoHO) implementation, expanding access research, and continuing to champion the unique plasma supply chain all in service of reliable patient access to plasma-derived therapies worldwide.
Click here to read PPTA’s 2025 Annual Report